Clinical and radiological outcomes of a stemless reverse shoulder implant: a two-year follow-up in 56 patients

Christian Schoch, MD\textsuperscript{a,}\textsuperscript{*}, Johannes E. Plath, PhD\textsuperscript{b}, Leander Ambros, MD\textsuperscript{a}, Michael Geyer, MD\textsuperscript{d}, Michael Dittrich, MD\textsuperscript{d}

\textsuperscript{a}Department for Shoulder and Elbow Surgery, St. Vinzenz-Klinik Pforzheim, Pforzheim, Germany
\textsuperscript{b}Department of Trauma, Orthopaedic, Plastic and Hand Surgery, University Hospital of Augsburg, Augsburg, Germany

\textbf{Article Info}

\textbf{Keywords:}
- RSA
- Stemless
- Cuff arthropathy
- Stemless implant

\textbf{Background:} Since the introduction of stemless anatomic shoulder arthroplasty, many studies have been published on anatomic implants. For reverse stemless implants, however, there are only a few clinical follow-up studies available. The current clinical case series aims to present clinical and radiological outcomes of a new stemless reverse prostheses system (Lima Shoulder Modular Replacement stemless).

\textbf{Methods:} We prospectively evaluated the outcome of 56 stemless total shoulder arthroplasties in 56 patients with a mean age of 61.2 years (46-76 years) at the time of implantation at a minimum follow-up of 24 months (range 24-41 months). All patients were physically and radiologically examined. Clinical outcomes were evaluated by using the Constant-Murley Score and the Subjective Shoulder Value.

\textbf{Results:} The mean Subjective Shoulder Value was 84.27\% at the latest follow-up. Significant improvements from preoperative to latest follow-up were documented for Constant-Murley Score (34.9 pts to 74.43 pts, \(P < .001\)) and active range of motion (abduction 72° to 130°, flexion 36° to 138°, and external rotation 16° to 28°). There was one complete loosening of the humeral component without reoperation. Radiolucency lines were observed in anteroposterior or axial radiographs at the humeral component in 23\% of the cases, most of them in anteroposterior view at the calcar region. Radiolucency line findings did not affect clinical outcomes. Major complications or revisions did not occur so far.

\textbf{Conclusion:} At short-term follow-up, stemless reverse shoulder systems show comparable clinical and radiological outcomes compared to stemmed reverse implants in the literature.

\textbf{Level of evidence:} Level IV; Case Series; Treatment Study

Reverse shoulder arthroplasty (RSA) is an effective tool in the portfolio of the shoulder surgeon treating massive rotator cuff tears, cuff tear arthropathy, and primary osteoarthritis of the shoulder with severe eccentric glenoid wear (B2/3 glenoid according to Walch) or in older patients with osteoarthritis and a “cuff at risk.”\textsuperscript{1,15,20} The main complaints of these patients are pain and loss of shoulder function (range of motion [ROM] and strength). The number of RSA implantation is rapidly increasing, along with a 5-fold increase in the US market within the past 10 years.\textsuperscript{19}

From the classical stemmed “Grammont”-style prosthesis up to now, there was a significant change in design, especially at the glenoid side, but also on the humeral side. In 2004, the stemless anatomic implants emerged on the market. One of the rare stemless reverse implants currently available on the European market is the Lima Shoulder Modular Replacement (SMR) stemless reverse prosthesis (Lima Corporate, Villanovan, San Daniele del Friuli, Italy). The theoretical advantages of stemless reverse implants are equivalent to the postulated benefits of the stemless anatomical designs: preservation of the humeral bone stock, reduced peri-prosthetic fracture risk, higher adaptability during implantation, easier implantation in cases of altered anatomy such as post-traumatic malunion, as well as less complex revision surgery in case of failure of the stemless device.\textsuperscript{5,5,8,19} Since introducing the stemless reverse designs, there have been only a few studies reporting on short- and mid-term outcomes.\textsuperscript{7,3,4,13,17}

The first stemless implant, which was introduced in 2004, was the Total Evolutive Shoulder System (TESS; Biomet, Warsaw, IN, USA) which used a stemless “corola” design as a metaphysis anchor.

Despite promising clinical and radiological results of this reverse system, the TESS was followed by the Zimmer Biomet Nano comprehensive. The Nano reverse system was withdrawn from the market by Zimmer. In 2015, Lima (Lima Corporate, Villanovan, San Daniele del Friuli, Italy) released its SMR stemless shoulder system. This is a convertible system that contains two humeral-sided parts...
for reverse configuration (humeral core component and reverse liner). The humeral core component is built of trabecular titanium, which is expected to improve ingrowth. When used in reverse configuration, a metallic reverse liner is impacted into the humeral core component. This metallic liner, manufactured out of Cobalt-Chrome-Molybdenum alloy, then articulates with an all-polyethylene glenosphere. The SMR stemless is usable in Europe; within the United States, the Food and Drug Administration (FDA) approval is pending. To the best of our knowledge, no clinical results on the Lima SMR stemless implant, neither anatomic nor reverse, have been published so far.

The following study aimed to evaluate clinical and radiological results of the Lima SMR stemless reverse implant at short-term follow-up.

**Materials and methods**

Ethical approval for this study protocol was granted by our local ethics committee board. Consent of each patient was obtained. All patient data were anonymized before analysis.

**Study population**

From January 2016 to November 2018, 59 stemless reverse total shoulder arthroplasties in 59 patients (23 women and 36 men) were planned. Of these prospectively included 59 patients, 56 ended up with a stemless implant. Fifty-two of the initial 56 patients could be followed up with a minimum duration of 24 months (range 24–47).

The following indications for RSA were included: not repairable rotator cuff tears, cuff tear arthropathy, posttraumatic arthritis of the glenohumeral joint, B2/3 glenoid according to Walch classification, and osteoarthritis with a “cuff at risk” (Table I). Patients with rheumatoid arthritis, severe osteoporosis, or large subchondral cysts at the metaphysis were excluded from our study. For the first cohort in our clinic, we decided to operate only on patients younger than 70 years because of the expected good bone quality. For osteoporosis and cysts, there was no specific screening except the plain x-ray which was taken for preoperative planning. Three patients were, therefore, not operated with a stemless implant. During the study period, all patients fitting the inclusion criteria were operated with a stemless implant. Three patients refused to take part in the follow-up and were seen as dropouts. One patient died in a car accident, unrelated to the implant. So, in conclusion, we managed to follow up 52 out of 56 patients for at least 2 years (Fig. 1).

The indications for reverse shoulder implantation in the study population are presented in Table I.

**Surgical technique and rehabilitation**

C.S. performed all surgeries with the patient under general anesthesia combined with an interscalene catheter and single-shot antibiotics in beach chair position, using a deltopectoral approach.

Arthrotomy was performed by resecting the upper third of the subscapularis tendon, and the lower part of the subscapularis tendon was preserved. Teres minor and as much infraspinatus as possible were spared. The intramedullary resection guide was used, and the level of resection was defined by the anatomical neck, thus

---

**Figure 1** Inclusion/exclusion flowchart.

**Table I**

| Indications for implantation                        | Count |
|----------------------------------------------------|-------|
| Primary osteoarthritis with B2/3 glenoid           | 8     |
| Primary osteoarthritis with R.C. at risk           | 13    |
| Cuff tear arthropathy                              | 29    |
| Secondary osteoarthritis (posttraumatic, instability) | 6     |

---
resulting in a 142° resection. The baseplate and glenosphere were implanted in a standardized fashion.

The size (width and depth) of the core at the glenoid side was determined using the sizing tool (XS, S, M, L). The reamer was used under strict control to preserve the cortical ring. Cancellous bone from the resected humeral head was used for impaction grafting before implanting the core implant into the cortical ring. Trial inlays were used to assess a sufficient tension of the deltoid muscle. After reduction, there was no need for further repositioning of the subscapularis tendon.

Within the first 4 weeks after surgery a 15° abduction pillow (SAS comfort, Medi, Bayreuth, Germany) was used for pain-dependent immobilization and during sleep. From the second week on, active ROM was explicitly trained. Combined adduction and internal rotation as well as weightbearing with more than 5 kg were not allowed for 6 weeks.

Clinical assessment

The clinical results were assessed by an independent board-certified orthopedic surgeon prospectively before the operation and at 12 months and with a minimum of 24 months follow-up using the absolute Constant-Murley Score (CMS) as well as the age- and gender-corrected CMS and the Subjective Shoulder Value (SSV). For strength measurements in abduction, we used the digital force gauge IsoForceControl V1.1 (MDS Medical Device Solutions AG, Oberburg, Switzerland) at the wrist in 90° of shoulder abduction.

ROM was measured by using a goniometer.

Radiological assessment

For radiologic follow-up, we analyzed true anteroposterior and axillary view radiographs taken at the latest follow-up. Postoperative radiographs were available for comparison. Radiolucency was assessed at the humeral side according to the classification of Moroder et al. Here, the humeral component is divided into four zones on anteroposterior and axillary views, with each zone corresponding to a 45° angle. In total, eight zones were defined (Fig. 2).

Clinical assessment

The clinical results were assessed by an independent board-certified orthopedic surgeon prospectively before the operation and at 12 months and with a minimum of 24 months follow-up using the absolute Constant-Murley Score (CMS) as well as the age- and gender-corrected CMS and the Subjective Shoulder Value (SSV). For strength measurements in abduction, we used the digital force gauge IsoForceControl V1.1 (MDS Medical Device Solutions AG, Oberburg, Switzerland) at the wrist in 90° of shoulder abduction.

ROM was measured by using a goniometer.

Radiological assessment

For radiologic follow-up, we analyzed true anteroposterior and axillary view radiographs taken at the latest follow-up. Postoperative radiographs were available for comparison. Radiolucency was assessed at the humeral side according to the classification of Moroder et al. Here, the humeral component is divided into four zones on anteroposterior and axillary views, with each zone corresponding to a 45° angle. In total, eight zones were defined (Fig. 2).

### Table 2

Graduation of radiolucency.

| Radiolucency grade | Seen on x-ray                              |
|-------------------|--------------------------------------------|
| 0                 | No sclerosis                               |
| 1                 | Sclerosis and less than 1 mm space         |
| 2                 | Sclerosis with more than 1 mm space        |
| 3                 | radiologic loosening of the implant        |

The latest radiographs were rated by three independent observers. Radiolucency was defined as a loss of the bone adjacent to the implant and graded from 0 to 3, as shown in Table II. The glenoid component was not evaluated for this study as it is a standard component used in the stemmed and the stemless implant.

Statistical analysis

Data were gathered and sorted using MS-Excel 16/365 (Microsoft, Seattle, WA, USA), while SPSS 24.0 (IBM, Armonk, NY, USA) was used for statistical analysis. The Shapiro-Wilk test was used to test for normal distribution. Parametric data were analyzed using the t-test. For nonparametric data, we performed either the
Wilcoxon signed-rank test for comparing preoperative to postoperative data or the Mann-Whitney U test for analyses between groups. The level of significance was set at $P < .05$.

Fleiss’ Kappa was calculated for interobserver reliability in the radiographic evaluation.

### Results

#### Study population

In 56 of the scheduled 59 patients, a stemless reverse system was implanted. In three patients planned for a stemless implant, a good primary fixation of the implant was not achievable because of a too-small metaphysis; therefore, a stemmed implant was used instead, and the cases were excluded from the study. Thus, 56 cases were available for evaluation (Fig. 2).

The mean age of the included patients was 61.2 years (range 46–76 years) at the time of surgery (male 62%/ female 38%). The average follow-up duration was $29.3 \pm 6.2$ (range 24–47) months. One patient died because of a car accident and was lost to follow-up. Three patients were not willing to continue follow-up, one due to the distance to our clinic and two because of the COVID-19 pandemic, resulting in a follow-up rate of 93% ($n = 52$).

One gross loosening was seen on the x-ray. Interestingly the patient did quite well and wanted no revision. No other complications led to revision surgery.

#### Functional results

Our survey revealed statistically significant improvements for SSV and the absolute and corrected CMS as well as all its subcategories: pain, activities of daily living, ROM, and strength.

| Follow-up 1 | Mean | SD | $P$ value 1 vs. 0 | Mean | SD | $P$ value 2 vs. 1 |
|-------------|------|----|-----------------|------|----|-----------------|
| Flexion, $^a$ | 87   | 24.5 | .000 | 127  | 20.3 | .000 |
| Abduction, $^a$ | 72   | 22.7 | .000 | 111  | 19.0 | .000 |
| External rotation, $^a$ | 15   | 16.57 | .000 | 25   | 11.82 | .000 |
| Pain | 5.27 | 2.36 | .000 | 12.24 | 2.08 | .000 |
| Strength | 3.58 | 4.45 | .000 | 12.42 | 3.93 | .000 |
| ADL | 8.95 | 2.76 | .000 | 14.15 | 2.1 | .000 |
| ROM | 17.1 | 5.06 | .000 | 25.84 | 3.91 | .000 |
| CMS, absolute | 34.9 | 9.82 | .000 | 64.6 | 9.34 | .000 |
| CMS, relative | 37.9 | 10.54 | .000 | 70.28 | 10.05 | .000 |
| SSV | 35.00 | 15.06 | .000 | 74.0 | 11.52 | .000 |

$SD$, standard deviation; $ADL$, activities of daily living; $ROM$, range of motion; CMS, Constant-Murley Score; SSV, Subjective Shoulder Value.

![Figure 4](image_url) Examples for radiological outcomes. (a) No RLL. (b) Grade 1 ap: in zone 1 and 4; axillary view in zone 5. (c) Grade 2 ap: in zone 1; axillary view in zone 5, grade 1 zone 6.
Gains in active and passive ROM were seen in all planes of motion (each \( P < .001 \)). These results were consistent from the first follow-up after 1 year to the second follow-up with further significant improvement in all categories (\( P < .001 \)) but external rotation (Table III, Fig. 3).

**Radiological results**

Complete x-ray imaging was available for all 52 patients. The analysis showed no periprosthetic fracture or dislocation. We observed one gross loosening of the humeral component, which consolidated in a stable situation but at a different humeral inclination angle (120°). Analyzing the x-rays, we saw the fault on our implantation, the core does not have the necessary depth of seating in the implantation. All other implants did not show signs of movement of the core.

Overall, we observed radiolucency lines (RLLs) in 12 patients (23.1%). Most lucencies appeared in zone 1 (11 patients), zone 5 (9 patients), zone 4 (6 patients), and zone 3 (2). Patients with radiolucencies did not differ regarding age, follow-up, CMS, or functional results compared to patients without radiolucent lines. RLLs < 1 mm were seen in 10 arthroplasties (19.2%), RLLs > 1 mm (grade 2) were observed in 2 cases (3.8%).

Radiological stress shielding was not observed. Figure 4 shows examples for the different radiological outcome options.

Interrater reliability for the radiological analysis was assessed between observers C.S., M.D., and L.A. The Fleiss-Kappa was determined at \( k = 0.82 \) (almost perfect agreement).
C. Schoch, J.E. Plath, L. Ambros et al. JSES International 5 (2021) 1042–1048

Complications

No patient had to be revised up to now due to implant-related complications. One patient was revised because of a deep infection leaving the implant in situ. Another patient was revised to a stemmed revision implant for a periprosthetic fracture after a fall down 12 stairs (Fig. 5).

One implant did move significantly during rehabilitation but showed stable consolidation at a 120° angle after 10 weeks instead of 4 weeks of immobilization (Fig. 6).

Discussion

The aim of this study was to evaluate the Lima SMR reverse stemless prosthesis in functional outcomes and radiological results of the humeral component.

To our knowledge, this is the first short-term follow-up series of the Lima SMR reverse stemless system.

We were able to demonstrate significant improvements in ROM. Abduction increased from 72° to 130°, flexion from 86° to 138°, and external rotation from 16° to 28°.

For the TESS system, Kadum et al11 showed an increase in abduction from 30° to 110° and in flexion from 50° to 110° in a cohort of 16 patients with a mean follow-up duration of 39 months. Teissier et al12 demonstrated a raise in flexion from 96° to 143° and in external rotation from 26° to 39° in 91 RSAs with a mean follow-up duration of 41 months.12,13 Ballas and Béguin published regarding the TESS in a cohort of 56 patients and with a minimum follow-up duration of 58 months a gain in flexion from 79° to 140° and in external rotation from 13° to 45°.2 According to the literature, the Lima SMR Reverse in our study reaches similar results in ROM with even higher levels in abduction.

Significant improvements from preoperative to latest follow-up were documented in CMS from 34.9 pts to 74.4 pts, P < .001. The sex- and age-related CMS raised from 37.8 pts to 81 pts and the SSV from 35% to 64.3% after 2 years of follow-up.

For the “stemless” Verso prosthesis, Levy et al published their results with a follow-up of 2 to 7 years. There was an increase in the SSV from 8% preoperatively to 85% postoperatively and in the CMS from 14 pts to 59 pts. The age- and sex-related CMS improved from 21 pts to 86 pts.14

Moroder et al16 showed in their matched control in which they compared 29 patients with stemless TESS vs. 24 patients with stemmed RSA with a mean follow-up duration of 34.2 months, a CMS with 65.4 pt and an SSV with 86.6%.

Ballas and Béguin published an increase in the CMS in a midterm follow-up of 58 months from 29 pts to 62 pts.

The average age in our cohort was 61.2 years, which seems to be lower than that in the existing literature, where the average age is reported to be over 70 years.14,18

The radiological results are comparable to other implants. There was one complete loosening of the humeral component due to failure in implantation and, additionally, not following the initial rehabilitation protocol (patient started with weightlifting in the third week). Interestingly, the prosthesis gained clinical stability at 120° and still is not revised.

Radiolucencies were observed in anteroposterior or axial radiographs at the humeral component in 23.1% of the cases and most often occurred in zone 1 and 5. We believe that this happens because of an intraoperative effect of the most cranial and most caudal points of reaming, thus maybe a bit of eccentric reaming because we could see the “lucencies” in zone 1 and 5 in the direct postoperative x-rays as well as in the follow-up x-rays in all these cases. The lucencies in zone 3 and 4 appeared in the later follow-up (24 months, plus). So, the latter eight patients seem to have “real” lucency lines, which results in 14% overall.

However, we could not show any impact of the RLLs on the clinical outcome.

We see comparable results (23%) in the shorter follow-up compared to the literature about radiolucencies appearing in stemless implants. Beck et al published for the TESS prosthesis 38.8% of humeral RLL in 8 years of follow-up in 48 RSAs without functional impairment.

In discussing complications, a stemless reverse implant seems to be a safe procedure (Fig. 7).

Kadum et al showed in a 35-month follow-up of 49 patients with the TESS no implant loosening and a reduction of the VAS at rest from 30 down to 10 and from 65 down to 10 during activity.

Ballas and Béguin reported various complications such as one humeral bone fracture without consequences, five incidences of scapular notching, and one instability that lead to revision but no loosening at the humeral side.

Figure 7 Example of stemless reverse in fracture sequelae.
The biggest patient group was published by Teissier et al. in 2015, again using the TESS. Ninety-one stemless cases with a minimum follow-up duration of 24 months. No loosening was reported, but there was 19% scapular notching. Three complications appeared. One persistent instability with recurrent dislocations needed a revision surgery with a higher polyethylene implant. One patient suffered a spine fracture, and one patient had a traumatic clavicle fracture after a fall.

Limitations

This study has some limitations. The study design is a prospective clinical nonrandomized outcome study. There is underlying bias due to the inclusion criteria of age below 70 years which implies good bone quality. The cohort in our study is compared to that of younger age in other studies. The reason is that the indication for a new stemless implant, in our opinion, was younger patients with a good bone stock and lack of osteoporosis, for good fixation. We did not start implanting in older patients because of the fear of lower bone quality. Now, as we see no severe loosening, the indication for stemless use might be expanded. Since, to our knowledge, this is the first study about the Lima SMR stemless, we could only compare our results to studies that used different implants.

Conclusion

The Lima SMR stemless reverse shows promising short-term results in clinical, functional, and radiologic outcomes. The results are comparable to those of other reverse arthroplasties. Mid- to long-term results need to be provided in further studies.

Disclaimers:

Funding: The annual symposium of the department is sponsored with 800€ by Lima (as well as Arthrex, Medi, Langermeier, Medacta, AAP). No personal benefit is taken by any of the authors.

Conflicts of interest: The authors, their immediate families, and any research foundation with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article.

References

1. Alentorn-Geli E, Wanderman NR, Assenmacher AT, Sperling JW, Cofield RH, Sanchez-Sotelo J. Anatomic total shoulder arthroplasty with posterior capsular plication versus reverse shoulder arthroplasty in patients with biconcave glenoids: a matched cohort study. J Orthop Surg (Hong Kong) 2018;26:2309499018768570. https://doi.org/10.1177/2309499018768570.
2. Ballas R, Beşgin L. Results of a stemless reverse shoulder prosthesis at more than 58 months mean without loosening. J Shoulder Elbow Surg 2013;22:e1-6. https://doi.org/10.1016/j.jse.2012.12.005.
3. Beck S, Patalsis T, Busch A, Dittrich F, Wegner A, Landgraeben S, et al. Knöchenumbauprozesse [Stress-shielding] bei schafftefrischer anatomischer press-fit Schultertotalendoprothese. Z Orthop Unfall 2020. https://doi.org/10.1055/a-1079-6549.
4. Churchill RS, Athwal GS. Stemless shoulder arthroplasty-current results and designs. Curr Rev Musculoskelet Med 2016;9:10-6. https://doi.org/10.1007/s12178-016-0320-4.
5. Churchill RS, Chuiwarda C, Wiater JM, Friedman R, Freehill M, Jacobson S, et al. Clinical and radiographic outcomes of the simplicit canal-sparing shoulder arthroplasty system: a prospective two-year multicenter study. J Bone Joint Surg Am 2016;98:552-60. https://doi.org/10.2106/JBJS.15.00181.
6. Gilbart MK, Gerber C. Comparison of the subjective shoulder value and the Constant score. J Shoulder Elbow Surg 2007;16:717-21. https://doi.org/10.1016/j.jse.2007.02.123.
7. Habermeyer P, Lichtenberg S, Tauber M, Magosch P. Midterm results of stemless shoulder arthroplasty: a prospective study. J Shoulder Elbow Surg 2015;24:1463-72. https://doi.org/10.1016/j.jse.2015.02.023.
8. Harmer L, Throckmorton T, Splinger JW. Total shoulder arthroplasty: are the humeral components getting shorter? Curr Rev Musculoskelet Med 2016;9:17-22. https://doi.org/10.1016/j.crrms.2016.01-2931-3.
9. Hawi N, Magosch P, Tauber M, Lichtenberg S, Habermeyer P. Nine-year outcome after anatomic stemless shoulder prosthetic clinical and radiologic results. J Shoulder Elbow Surg 2017;26:1609-15. https://doi.org/10.1016/j.jse.2017.02.017.
10. Huguet D, De Clercq G, Rio B, Teissier J, Zipoli B. Results of a new stemless shoulder prosthesis: radiologic proof of maintained fixation and stability after a minimum of three years follow-up. J Shoulder Elbow Surg 2010;19:847-52. https://doi.org/10.1016/j.jse.2009.12.009.
11. Kadum B, Mukta S, Englund E, Sayed-Noor A, Sjöden G. Clinical and radiologic outcome of the Total Evolutive Shoulder System (TESS®) reverse shoulder arthroplasty: a prospective comparative non-randomised study. Int Orthop 2014;38:1001-6. https://doi.org/10.1007/s00264-013-2277-7.
12. Katolik LI, Romeo AA, Cole BJ, Verma NN, Hayden JK, Bach BR. Normalization of the Constant score. J Shoulder Elbow Surg 2005;14:279-85. https://doi.org/10.1016/j.jse.2004.10.009.
13. Krükenberg A, McBurnie J, Bartsch S, Böhler N, Wiedemann E, Jost B, et al. Sidus stem-free shoulder system for primary osteoarthrosis: short-term results of a multicenter study. J Shoulder Elbow Surg 2018;27:1483-90. https://doi.org/10.1016/j.jse.2018.02.057.
14. Levy O, Narvani A, Hous N, Abraham R, Relwani J, Pradhan R, et al. Reverse shoulder arthroplasty with a cementless short metaphyseal humeral implant without a stem: clinical and radiologic outcomes in prospective 2- to 7-year follow-up study. J Shoulder Elbow Surg 2016;25:1362-70. https://doi.org/10.1016/j.jse.2015.12.017.
15. Mizuno N, Denard PJ, Rains P, Walch G. Reverse total shoulder arthroplasty for primary glenohumeral osteoarthrosis in patients with a biconcave glenoid. J Bone Joint Surg Am 2013;95:1297-304. https://doi.org/10.2106/JBJS.L00820.
16. Moroder P, Ernstbrunner L, Zweiger C, Seitzinger G, Skursky R, et al. Short to mid-term results of stemless reverse shoulder arthroplasty in a selected patient population compared to a matched control group with stem. Int Orthop 2016;40:2115-20. https://doi.org/10.1007/s00264-016-3249-5.
17. Schoch C, Huth J, Aghajev E, Baurer G, Mauch F. Die metaphysärische Venenprothese bei posttraumatischer und prinzipiell osteoarthrosis. Oeffe Extremitt 2011;8:273-81. https://doi.org/10.1007/s11178-011-0317-x.
18. Teissier P, Teissier J, Kouyoumdjian P, Asencio G. The TESS reverse shoulder arthroplasty without a stem in the treatment of cuff-deficient shoulder conditions: clinical and radiographic results. J Shoulder Elbow Surg 2015;24:45-51. https://doi.org/10.1016/j.jse.2014.04.055.
19. Trofa D, Rajaei SS, Smith EL. Nationwide trends in total shoulder arthroplasty and hemiarthroplasty for osteoarthritis. Am J Orthop (Belle Mead NJ) 2014;43:106-72. No doi.
20. Wright MA, Keener JD, Chamberlain AM. Comparison of clinical outcomes after anatomic total shoulder arthroplasty and reverse shoulder arthroplasty in patients 70 Years and older with glenohumeral osteoarthritis and an intact rotator cuff. J Am Acad Orthop Surg 2020;28:e222-9. https://doi.org/10.5435/JAAOS-D-19-00165.